Our Facilities are open & are following the latest covid-19 safety protocols. TO SPEAK WITH AN ADMISSIONS SPECIALIST, PLEASE CALL US AT 800-444-1554

Committed to your success

Medication-Assisted Treatment (MAT)

At Gosnold, we know a successful recovery does not end with the completion of a treatment plan; we offer ongoing recovery support for our patients and their families.  We are committed to the community and provide family education, school-based counseling, medical care integration, and support prevention coalitions.

A young woman pours the pills out of the bottle

Medication Assisted Treatment (MAT)

Gosnold utilizes two different medications (Vivitrol & Suboxone) in our Medication Assisted Treatment (MAT) programs.  All patients participating in the MAT program will be required to attend weekly MAT support groups for the first three months they are receiving medication and then an assessment will be made for continued level of care needed.

MAT combined with counseling and behavioral therapies can dramatically decrease the likelihood of relapse, allowing people to continue school or work while receiving treatment.  MAT treatment options like Suboxone and Vivitrol help patients maintain a normal life while reducing side effects of withdrawal and curbing cravings that can lead to relapse.


One treatment option uses a medication called Naltrexone to help block cravings and euphoric effects of opiate drugs.  The injectable form of Naltrexone, Vivitrol, is an extended release formulation that lasts for approximately one month.  The medication can help patients during the challenging early stages of recovery.

Patients in the Vivitrol MAT program are evaluated by physicians and nurse practitioners with expertise in substance use disorders who supervise a clinical team that administers the monthly injection and provides the patients with support, including counseling, group therapy and case management


Suboxone, a partial opioid agonist, is an additional treatment option offered at Gosnold.  Suboxone is utilized for the treatment of opiate use disorders.   Suboxone contains two active ingredients: buprenorphine and naloxone.   Buprenorphine, the primary ingredient, attaches to the same receptors as an opiate does, but without allowing the euphoric effect, which can lead to reduced cravings and diminish withdrawal symptoms.  Naloxone, the second ingredient, is intended to help prevent misuse of the medication.

Patients receiving Suboxone are monitored by physicians and nurse practitioners, as well as a clinical team that provide individual therapy and group therapy options.  It is also suggested that all patients receiving Suboxone treatment attend weekly recovery meetings.

The MAT program has been shown to:

  • Improve patient survival
  • Increase ability to stay in treatment
  • Decrease illegal opioid use and activity
  • Increase patients ability to complete school and hold jobs
  • Improve birth outcomes among pregnant women with substance use disorders

Your Story Means The World To Gosnold.

For more general inquiries, including admission to or information about our programs, employment opportunities, or other general information, please call 508-540-6550. For more information about our mental health and addiction treatment programs, contact us at help@gosnold.org.

Ready to Join the Cause? Become A Part of the Gosnold Story

Skip to content